3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1223
Neoplasms
1041
Carcinoma, Non-Small-Cell Lung
755
Prostatic Neoplasms
693
Colorectal Neoplasms
593
Lung Neoplasms
574
Pancreatic Neoplasms
402
Leukemia, Myeloid, Acute
399
Neoplasm Metastasis
387
Multiple Myeloma
374
Ovarian Neoplasms
372
Stomach Neoplasms
317
Carcinoma, Hepatocellular
303
Melanoma
282
Recurrence
281
Brain Neoplasms
281
Squamous Cell Carcinoma of Head and Neck
268
Head and Neck Neoplasms
237
Endometrial Neoplasms
235
Glioblastoma
234
Triple Negative Breast Neoplasms
230
Precursor Cell Lymphoblastic Leukemia-Lymphoma
226
Uterine Cervical Neoplasms
225
Lymphoma
224
Hematologic Neoplasms
200
Sarcoma
199
Urinary Bladder Neoplasms
197
Esophageal Neoplasms
191
Carcinoma, Renal Cell
190
Lymphoma, Non-Hodgkin
176
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
1 year
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled